|

Autologous HuCD19 ( Anti-CD19)CAR T cells Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • B-Lymphocytic Leukemia, Chronic1
  • B-Cell Chronic Lymphocytic Leukemia1
  • Leukemia, Acute Lymphoblastic1
  • Leukemia, Lymphocytic, Chronic, B-Cell1
  • Lymphoblastic Lymphoma1

Bethesda, Maryland1 trial

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

National Institutes of Health Clinical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.